44
44052TAB7
Horizon Pharma Investment Limited
Could not find a ticker for this position, may be a filing error
A biopharmaceutical group that develops and sells medicines for rare, autoimmune, and severe inflammatory diseases, including Tepezza for thyroid eye disease and Krystexxa for chronic gout. It began in 2005 in Illinois and merged in 2010 with Swiss firm Nitec Pharma, itself a spin-off from Merck KGaA. In October 2023 the whole group, including this Irish-registered subsidiary, was bought by Amgen.
CONVERTIBLECUSIP: 44052TAB7HealthcareIE1 derivative reporter
2.5% Exchangeable Senior Notes due March 15, 2022
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
